Cognitive impairment among prostate cancer patients: An overview of reviews

European Journal of Cancer Care

Volumn 26, Issue 6, 2017, Pages

  Treanor, C J ^a   Li, J ^a   Donnelly, M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

prostate cancer; psychological; review; therapy

Indexed keywords

ANTIANDROGEN;

COGNITIVE DEFECT; HUMAN; INCIDENCE; MALE; PREVALENCE; PROSTATE TUMOR; PSYCHOLOGY;

ANDROGEN ANTAGONISTS; COGNITIVE DYSFUNCTION; HUMANS; INCIDENCE; MALE; PREVALENCE; PROSTATIC NEOPLASMS;

EID: 85012873851     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/ecc.12642     Document Type: Review

References (55)

1. Ahles, T. A., & Saykin, A. J. (2007). Candidate mechanisms for chemotherapy-induced cognitive changes. Nature Reviews. Cancer, 7(3), 192–201.
2. Alibhai, S. M. H., Gogov, S., & Allibhai, Z. (2006). Long-term side effects of androgen deprivation therapy in me with non-metastatic prostate cancer: A systematic literature review. Critical Reviews in Oncology/Hematology, 60, 201–215.
3. Alibhai, S. M. H., Mahmoud, S., Hussain, F., Nagle, G., Tannock, I., Fleshner, N., … Duff Canning, S. (2010). Levels of sex hormones have limited effect on cognition in older men with or without prostate cancer. Critical Reviews in Oncology/Hematology, 73(2), 167–175.
4. Almeida, O. P., Waterreus, A., Spry, N., Flicker, L., & Martins, R. N. (2004). One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology, 29(8), 1071–1081.
5. Artherholt, S. B., & Fann, J. R. (2012). Psychosocial care in cancer. Current Psychiatry Reports, 14(1), 23–29.
6. Beauchet, O. (2006). Testosterone and cognitive function: Current clinical evidence of a relationship. European Journal of Endocrinology, 155(6), 773–781.
7. Beer, T. M., Bland, L. B., Garzotto, M., Ryan, C. W., & Janowsky, J. S. (2004). Effect of high-dose estrogen on memory in men with prostate cancer. In ASCO annual meeting proceedings (pp. 4650). Virginia, USA.
8. Beer, T. M., Bland, T. M. L. B., & Garzotto, M. (2006). Testosterone loss and estradiol administration modify memory in men. Journal of Urology, 175(1), 130–135.
9. Biegler, K. A., Chaoul, M. A., & Cohen, L. (2009). Cancer, cognitive impairment, and meditation. Acta Oncologica (Stockholm, Sweden), 48(1), 18–26.
10. Bloomfield, D. J., Shilling, V. M., Edington, T. L. & Jenkins, V. A. (2004). A longitudinal pilot study to investigate whether hormonal therapy for prostate cancer affects cognition. In ASCO annual meeting proceedings (pp. 4646). Virginia, USA.
11. Bussiere, J. R., Beer, T. M., Neiss, M. B., & Jarowsky, J. S. (2005). Androgen deprivation impairs memory in older men. Behavioral Neuroscience, 119(6), 1429–1437.
12. Centre for Reviews and Dissemination (2009). Core principles and methods for conducting a systematic review of health interventions. In Centre for Reviews and Dissemination, University of York (Ed.) Systematic reviews: CRD's guidance for undertaking systematic reviews in health care (3rd edn). York: York Publishing Services Ltd.
13. Chao, H. H., Hu, S., Ide, J. S., Uchio, E., Zhang, S., Rose, M., … Li, C. S. (2013). Effects of androgen deprivation on cerebral morphometry in prostate cancer patients – An exploratory study. PLoS ONE, 8(8), e72032.
14. Chen, A. C., & Petrylak, D. P. (2004). Complications of androgen deprivation therapy in men with prostate cancer. Current Oncology Reports, 6(3), 209–215.
15. Cherrier, M. M., Aubin, S., & Higano, C. S. (2009). Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psycho-Oncology, 18(3), 237–247.
16. Cherrier, M. M., Rose, A. L., & Higano, C. (2003). The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. The Journal of Urology, 170, 1808–1811.
17. Chism, K., & Kunkel, E. J. S. (2009). Prostate cancer: issues in psychosomatic medicine. Current Psychiatry Reports, 11(3), 205–210.
18. DiBlasio, C. J., Hammett, J., Malcolm, J. B., Judge, B. A., Womack, J. H., Kincade, M. C., … Derweesh, I. H. (2008). Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer. The Canadian Journal of Urology, 15(5), 4249–4256.
19. Droz, J.-P., Balducci, L., Bolla, M., Emberton, M., Fitzpatrick, J. M., Joniau, S., … Sternberg, C. N. (2010). Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Critical Reviews in Oncology/Hematology, 73(1), 68–91.
20. Falci, C., Morello, E., & Droz, J. P. (2009). Treatment of prostate cancer in unfit senior adult patients. Cancer Treatment Reviews, 35(6), 522–527.
21. Green, H. J., Pakenham, K. I., & Gardiner, R. A. (2005). Cognitive deficits associated with cancer: a model of subjective and objective outcomes. Psychology, Health & Medicine, 10(2), 145–160.
22. Green, H. J., Pakenham, K. I., Headley, B. C., Yaxley, J., Nicol, D. L., & Mactaggart, P. N., … Gardiner, R. A. (2002). Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU International, 90, 427–432.
23. Green, H. J., Pakenham, K. I., Headley, B. C., Yaxley, J., Nicol, D. L., Mactaggart, P. N., … Gardiner, R. A. (2004). Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU International, 93(7), 975–979.
24. Grossmann, M., & Zajac, J. D. (2011). Androgen deprivation therapy in men with prostate cancer: How should the side effects be monitored and treated? Clinical Endocrinology, 74(3), 289–293.
25. Gruca, D., Bacher, P., & Tunn, U. (2012). Safety and tolerability of intermittent androgen deprivation therapy: A literature review. International Journal of Urology, 19(7), 614–625.
26. Harrington, C. B., Hansen, J. A., Moskowitz, M., Todd, B. L., & Feuerstein, M. (2010). It's not over when it's over: Long-term symptoms in cancer survivors – A systematic review. International Journal of Psychiatry in Medicine, 40(2), 163–181.
27. Holzbeierlein, J. M. (2006). Managing complications of androgen deprivation therapy for prostate cancer. The Urologic Clinics of North America, 33(2), 181–190. vi.
28. Isbarn, H., Boccon-Gibod, L., Carroll, P. R., Montorsi, F., Schulman, C., Smith, M. R., … Studer, U. E. (2009). Androgen deprivation therapy for the treatment of prostate cancer: Consider both benefits and risks. European Urology, 55(1), 62–75.
29. Jamadar, R. J., Winters, M. J., & Maki, P. M. (2012). Cognitive changes associated with ADT: A review of the literature. Asian Journal of Andrology, 14(2), 232–238.
30. Janelsins, M. C., Kohli, S., Mohile, S. G., Usuki, K., Ahles, T. A., & Morrow, G. R. (2011). An update on cancer- and chemotherapy-related cognitive dysfunction: Current status. Seminars in Oncology, 38, 431–438.
31. Jenkins, V. A., Bloomfield, D. J., Shilling, V. M., & Edginton, T. L. (2005). Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU International, 96(1), 48–53.
32. Joly, F., Alibhai, S. M. H., Galica, J., Park, A., Yi, Q. L., Wagner, L., & Tannock, I. F. (2006). Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. The Journal of Urology, 176(6 Pt 1), 2443–2447.
33. Lange, M., Rigal, O., Clarisse, B., Giffard, B., Sevin, E., Barillet, M., Eustache, F., & Joly, F. (2014). Cognitive dysfunctions in elderly cancer patients: A new challenge for oncologists. Cancer Treatment Reviews, 40(6), 810–817.
34. Mitsiades, N., Correa, D., Gross, C. P., Hurria, A., & Slovin, S. F. (2008). Cognitive effects of hormonal therapy in older adults. Seminars in Oncology, 35(6), 569–581.
35. Mohile, S. G., Mustian, K., Bylow, K., Hall, W., & Dale, W. (2009). Management of complications of androgen deprivation therapy in the older man. Critical Reviews in Oncology/Hematology, 70(3), 235–255.
36. Mohile, S. G., Lacy, M., Rodin, M., Bylow, K., Dale, W., Meager, M. R., & Stadler, W. M. (2010). Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Critical Reviews in Oncology/Hematology, 75(2), 152–159.
37. Mottet, N., Prayer-Galetti, T., Hammerer, P., Kattan, M. W., & Tunn, U. (2006). Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU International, 98(1), 20–27.
38. Myers, J. S. (2009). A comparison of the theory of unpleasant symptoms and the conceptual model of chemotherapy-related changes in cognitive function. Oncology Nursing Forum, 36(1), E1–E10.
39. Nelson, C. J., Nandy, N., & Roth, A. J. (2007). Chemotherapy and cognitive deficits: Mechanisms, findings, and potential interventions. Palliative and Supportive Care, 5(3), 273–280. Available from: http://www.journals.cambridge.org/abstract_S1478951507000442 [last accessed 17 October 2014].
40. Nelson, C. J., Lee, J. S., Gamboa, M. C., & Roth, A. J. (2008). Cognitive effects of hormone therapy in men with prostate cancer: A review. Cancer, 113(5), 1097–1106.
41. Salminen, E., Portin, R., Korpela, J., Backman, H., Parvinen, L-M., Helenius, H., & Nurmi, M. (2003). Androgen deprivation and cognition in prostate cancer. British Journal of Cancer, 89, 971–976.
42. Salminen, E. K., Portin, R. I., Koskinen, A., Helenius, H., & Nurmi, M. (2004). Associations between serum testosterone fall and cognitive function in prostate cancer patients associations between serum testosterone fall and cognitive function in prostate cancer patients. Clinical Cancer Research, 10, 7575–7582.
43. Salminen, E. K., Portin, R. I., Koskinen, A. I., Helenius, H. Y. M., & Nurmi, M. J. (2005). Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer, 103, 1381–1387.
44. Scherr, D. S., & Pitts, W. R. (2003). The nonsteroidal effects of diethylstilbestrol: The rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. The Journal of Urology, 170(5), 1703–1708.
45. Shahinian, V. B., Kuo, Y. F., Freeman, J. L., & Goodwin, J. S. (2006). Risk of the “androgen deprivation syndrome” in men receiving androgen deprivation for prostate cancer. Archives of Internal Medicine, 166, 465–471.
46. Sharifi, N. (2005). Androgen deprivation therapy for prostate cancer. JAMA, 294(2), 238. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.294.2.238. [last accessed 10 November 2014]
47. Shea, B. J., Grimshaw, J. M., Wells, G. A., Boers, M., Andersson, N., Hamel, C., … Bouter, L. M. (2007). Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology, 7, 10.
48. Tombal, B. (2009). A holistic approach to androgen deprivation therapy: Treating the cancer without hurting the patient. Urologia Internationalis, 83(4), 373–378. Available from: http://www.karger.com
49. Treanor, C. J., Coyle, V., Passmore, P., Kee, F., & Donnelly, M. Developing an intervention to reduce cognitive impairment due to systemic cancer treatment (in preparation)
50. Trost, L. W., Serefoglu, E., Gokce, A., Linder, B. J., Sartor, A. O., & Hellstrom, W. J. G. (2013). Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement. The Journal of Sexual Medicine, 10, 84–101
51. Verhagen, P. C. M. S., Wissenburg, L. D., Wildhagen, M., Mickisch, G. H. J. (2008). Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (CPA) for metastatic prostate cancer. In 23rd annual congress of the European Association of Urology, Amsterdam, The Netherlands.
52. Wefel, J. S., Kayl, A. E., & Meyers, C. A. (2004). Neuropsychological dysfunction associated with cancer and cancer therapies: A conceptual review of an emerging target. British Journal of Cancer, 90(9), 1691–1696
53. Wright, J. L., Higano, C. S., & Lin, D. W. (2006). Intermittent androgen deprivation: Clinical experience and practical applications. The Urologic Clinics of North America, 33(2), 167–179, vi.
54. Wu, L. M., Diefenbach, M. A., Gordon, W. A., Cantor, J. B., & Cherrier, M. M. (2013). Cognitive problems in patients on androgen deprivation therapy: A qualitative pilot study. Urologic Oncology: Seminars and Original Investigations, 31, 1533–1538.
55. Ziółkowska, E., Zarzycka, M., Wiśniewski, T., & Zyromska, A. (2012). The side effects of hormonal therapy at the patients with prostate cancer. Contemporary Oncology (Poznań, Poland), 16(6), 491–497.